Featured

FDA Accepts NDA for Oral Semaglutide 25mg for Obesity

Novo Nordisk announced that the FDA accepted its New Drug Application (NDA) for a 25 mg oral formulation of Wegovy (semaglutide) for chronic weight ma...

Home/KnolSights/Regulatory Approvals/FDA Accepts NDA for Oral Semaglutide 25mg for Obesity